China’s Market Regulator Sets Sept 18 Hearing on Meituan’s Acquisition of Beijing Maiyatian

The notable signal is procedural rather than commercial: SAMR is testing whether remedy commitments actually cure competition concerns, in a public forum, rather than clearing the deal behind closed doors. That matters for platform M&A generally, since conditional approvals have become the default path and their enforcement credibility is now the binding constraint. Whether the hearing produces a substantive revision of the commitments, or merely ratifies them, is the open question for how other pending platform deals are structured.